Viera Tóthová, Pavol Dubinský, Ján Kliment, Ivan Režňák, Eva Takácsová, Iveta Vinarčíková-Mikšíková
Metastatic castration-resistant prostate cancer (mCRPC) predominantly involve bones, resulting in bone pain, skeleton-
related events, reduced quality of life and survival. Several options for the treatment of mCRPC are currently available,
including radium-223 dichloride. Radium-223 is the first alpha-particle emitter radiopharmaceutical with the benefit
in overall survival in patients with mCRPC with symptomatic bone metastases and no visceral involvement. Therapy
using radium-223 has shifted the role of nuclear medicine from bone pain palliation into the provision of the life-prolonging
agent. A multidisciplinary approach is essential for optimal selection of patients. Current treatment guidelines
established radium-223 in both pre- and post-chemotherapy en_settings. The review article deals with treatment indications
of radium-223, clinical effect assessment and practical recommendations for treatment of mCRPC based on personal
experience.